Lilly's Oral GLP-1 Franchise Poised for Dominance, But Execution and Pricing Risks Remain

What happened

Novo Nordisk is no longer viewed as a near-term threat, leaving Lilly's Tirzepatide to dominate the injectable obesity and Type 2 Diabetes markets for 1.5–2 years, while the newly approved oral Foundayo (orforglipron) is expected to capture $20B+ in 2030 sales. Retatrutide is set to monopolize the high-margin Class III Obesity market with no direct triple-agonist competition expected until around 2031. However, the DeepValue report flags that the current $948 stock price already prices in rapid scaling of Foundayo and sustained volume growth, despite net price resets and policy-linked downward pressure. The key 6–9 month hinge is whether Foundayo scales without supply or safety friction, especially after the FDA requested additional liver-injury data that could lead to label tightening. While the category expansion thesis is intact, the risk-reward is unfavorable at current multiples, supporting a WAIT rating until Q2–Q3 evidence confirms volume truly offsets price.

Implication

The valuation at ~33x P/E leaves no margin of safety; a more attractive entry is near $850, with trimming above $1,050, as confirmation of durable oral scaling and management's ability to offset price declines with volume is needed to sustain the premium.

Thesis delta

The bullish narrative of unopposed GLP-1 dominance shifts to a more cautious near-term outlook: while competitive threats have faded, the operational challenges of Foundayo scaling and net price compression under policy and competitor actions now dominate the risk-reward calculus. The thesis moves from 'buy on dominance' to 'wait for execution proof,' as the stock already prices in success and leaves limited room for disappointment on safety or supply.